PrescriptionDrugs.org

Metformin & Empagliflozin Interaction

Minor

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Learn more about Metformin →Learn more about Empagliflozin →

Overview

Metformin and empagliflozin (an SGLT-2 inhibitor) are commonly co-prescribed for type 2 diabetes and represent a guideline-recommended combination with complementary mechanisms. Empagliflozin has demonstrated cardiovascular and renal protective effects (EMPA-REG OUTCOME trial) that extend beyond glucose lowering. This combination is generally safe with a low risk of hypoglycemia.

How does this interaction occur?

Metformin reduces hepatic glucose production via AMPK. Empagliflozin inhibits the SGLT-2 transporter in the proximal renal tubule, blocking renal glucose reabsorption and causing glucosuria. These completely distinct mechanisms provide additive glycemic control. Empagliflozin also reduces blood pressure and body weight through natriuresis and osmotic diuresis. There is no pharmacokinetic drug-drug interaction between the two agents.

Clinical significance

The EMPA-REG OUTCOME trial showed empagliflozin reduced cardiovascular death, heart failure hospitalization, and renal progression versus placebo in patients with established cardiovascular disease. Metformin combined with empagliflozin provides synergistic metabolic benefits. Risk of hypoglycemia without insulin or secretagogue is low. Risk of mycotic genital infections and urinary tract infections increases with empagliflozin.

Management recommendations

No dose adjustment is needed for either drug when used together. Monitor renal function before starting empagliflozin (do not initiate if eGFR is below 30 mL/min/1.73 m2). Counsel patients on genital hygiene to reduce mycotic infection risk. Ensure adequate hydration. Hold both drugs if severe illness, surgery, or iodinated contrast is planned.

What to monitor

eGFR at baseline and periodically. Blood glucose and HbA1c every 3 months until stable. Blood pressure. Signs and symptoms of urinary tract infection or genital yeast infection. Assess for diabetic ketoacidosis symptoms if patient becomes acutely unwell.

Alternative options

If SGLT-2 inhibitor not tolerated, a DPP-4 inhibitor or GLP-1 receptor agonist may be added to metformin. Canagliflozin and dapagliflozin are alternative SGLT-2 inhibitors with similar profiles.

Frequently asked questions

References

  1. [Regulatory] Empagliflozin (Jardiance) FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s034lbl.pdf Accessed 2026-03-01.
  2. [Regulatory] Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM 2015. https://www.nejm.org/doi/10.1056/NEJMoa1504720 Accessed 2026-03-01.
  3. [Regulatory] Metformin Hydrochloride FDA Prescribing Information https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: